Regeneron Pharmaceuticals REGN Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Regeneron Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's current ratio?
- Regeneron Pharmaceuticals (REGN) reported current ratio of 3.6× in Q1 2026.
- How has Regeneron Pharmaceuticals's current ratio changed year-over-year?
- Regeneron Pharmaceuticals's current ratio decreased by 27.6% year-over-year, from 4.9× to 3.6×.
- What is the long-term trend for Regeneron Pharmaceuticals's current ratio?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's current ratio has grown at a 6.1% compound annual growth rate (CAGR), from 14× to 17.7×.
- What does current ratio mean?
- Whether the company has enough short-term assets to cover its short-term bills.
- How do you interpret current ratio?
- Above 1.0 means short-term assets cover short-term liabilities. Very high values can signal idle cash or bloated inventory/receivables rather than strength — there's a healthy middle, not 'more is better'.
- How does current ratio compare across companies?
- Comparable within an industry. Working-capital-light businesses can operate safely below 1.0 by collecting before they pay.